Key result
A six-week-old infant developed malignant hyperthermia triggered by sevoflurane, which resolved upon discontinuation of the anesthetic without the need for dantrolene.
Why the study?
There is a limited body of evidence regarding malignant hyperthermia presentation and diagnosis in neonates and infants.
Case Report (n=1)
No
This case highlights that malignant hyperthermia can present in very young infants and may resolve with discontinuation of the triggering agent alone.
Raises awareness of MH in neonates; leaves open whether dantrolene is invariably required.
A six-week-old 3.9-kg infant presented for microlaryngoscopy and diaphragmatic hernia repair. While positioning for laparoscopy after microlaryngoscopy, the infant developed muscle rigidity, worsening hypercarbia, tachycardia, and early hyperthermia. Sevoflurane was discontinued, and the clinical picture indicating malignant hyperthermia (MH) resolved without dantrolene. Subsequent genetic testing revealed that both the patient and his father carried a mutation in the RYR1 gene that is diagnostic for MH. This is the second youngest genetically confirmed case of MH. This case adds to a limited body of evidence regarding MH presentation and diagnosis in neonates and infants.
No takes yet. Share an insight, caveat, or question.
Edwards et al. (2022) conducted a case report in Malignant Hyperthermia (n=1). Sevoflurane was evaluated on Resolution of malignant hyperthermia symptoms. A six-week-old infant developed malignant hyperthermia triggered by sevoflurane, which resolved upon discontinuation of the anesthetic without the need for dantrolene.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: